Shopping Cart
Remove All
Your shopping cart is currently empty
MeTC7 is a vitamin D receptor (VDR) antagonist with antitumor activity that inhibits PD-L1 and may inhibit the growth of xenografts and transgenic tumors in vivo.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $46 | In Stock | In Stock | |
| 5 mg | $113 | In Stock | In Stock | |
| 10 mg | $213 | In Stock | In Stock | |
| 25 mg | $428 | - | In Stock | |
| 50 mg | $639 | - | In Stock | |
| 100 mg | $913 | 7-10 days | 7-10 days | |
| 1 mL x 10 mM (in DMSO) | $157 | - | In Stock |
| Description | MeTC7 is a vitamin D receptor (VDR) antagonist with antitumor activity that inhibits PD-L1 and may inhibit the growth of xenografts and transgenic tumors in vivo. |
| Targets&IC50 | VDR:2.9 μM |
| In vitro | MeTC7 disrupts the VDR-Ligand-binding domain in Silico. MeTC7 shows potent VDR inhibition activity with an IC50=2.9 μM. [1] Treatment with 250 nM MeTC7 for 18 h was able to inhibit the expression of RXRα and Importin-4 and induce PARP1 cleavage, thereby inhibiting the viability of ovarian cancer cells. [1] |
| In vivo | By intraperitoneal injection of 10 mg/kg MeTC7 was able to inhibit the growth of spontaneous transgenic TH-MYCN neuroblastoma and xenograft tumors in vivo. [1] |
| Synonyms | MeTC 7 |
| Molecular Weight | 618.65 |
| Formula | C32H48BrN3O4 |
| Cas No. | 1817841-22-7 |
| Smiles | O=C1N2C34[C@@]([C@]5(C)C(N2C(=O)N1C)(C=C3)C[C@@H](OC(CBr)=O)CC5)(CC[C@@]6(C)[C@]4(CC[C@@]6([C@@H](CCCC(C)C)C)[H])[H])[H] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 10 mg/mL(16.16 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.